Get started
Author

C. F. Pollera

Observed names: C F Pollera, C. Pollera, C.F Pollera, C.F. Pollera, Camillo F Pollera, Camillo F. Pollera, Camillo Francesco Pollera, Camillo Franco Pollera, CamilloF. Pollera
Observed institutions: Università degli Studi della Tuscia, Università Campus Bio-Medico, Ospedale Antonio Cardarelli, Ospedale Santa Chiara, Azienda Sanitaria Locale Viterbo, Sanofi (Italy), Ospedale di Belcolle, Ospedale Santa Maria Goretti, Carlo Forlanini Hospital, La Maddalena, Instituto Nazionale Tumori Regina Elena, Sapienza University of Rome
OpenAlex ID: A5109200310
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
1998 · V Lorusso, C.F Pollera, et al. · European Journal of Cancer · 286
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial
2011 · F. Cognetti, E.M. Ruggeri, et al. · Annals of Oncology · 225
PDF
Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study
1994 · C.F. Pollera, A. Ceribelli, et al. · Annals of Oncology · 184
Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model
1989 · Camillo F. Pollera, Diana Giannarelli · Cancer · 99
PDF
Adjuvant chemotherapy in muscle‐invasive bladder carcinoma
2006 · Enzo Maria Ruggeri, Diana Giannarelli, et al. · Cancer · 80
PDF
Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels
1997 · Camillo F. Pollera, Anna Ceribelli, et al. · Investigational New Drugs · 63
Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.
1990 · M Nardi, F Cognetti, et al. · Journal of Clinical Oncology · 60
Cisplatin-induced hepatic toxicity.
1987 · C F Pollera, F Ameglio, et al. · Journal of Clinical Oncology · 59
Single Colon Metastasis from Breast Cancer a Clinical Case Report
2005 · Carlo Signorelli, Donatella Pomponi-Formiconi, et al. · Tumori Journal · 41
Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects
1988 · CamilloF. Pollera, Paolo Marolla, et al. · Cancer Chemotherapy and Pharmacology · 37
Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial
2008 · F. Cognetti, E. M. Ruggeri, et al. · Journal of Clinical Oncology · 32
Sudden Death After Acute Dystonic Reaction to High-dose Metoclopramide
1984 · Camillo Francesco Pollera, Francesco Cognetti, et al. · The Lancet · 31
Weekly gemcitabine in advanced or metastatic solid tumors
1994 · Camillo F. Pollera, Anna Ceribelli, et al. · Investigational New Drugs · 28
Randomized open cross-over trial between Metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting
1984 · Francesco Cognetti, Paula Pinnarò, et al. · European Journal of Cancer and Clinical Oncology · 26
Long-term survival in locally advanced oral cavity cancer: An analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery
2005 · Enzo Maria Ruggeri, Paolo Carlini, et al. · Head & Neck · 24
Effective Control of CMF-Related Emesis with High-Dose Dexamethasone
1989 · Camillo F. Pollera, Mario Nardi, et al. · American Journal of Clinical Oncology · 22
Gemcitabine and Cisplatin in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Impact of Comorbidities on Safety and Efficacy Outcome
2005 · L. Moscetti, F. Nelli, et al. · Journal of Chemotherapy · 19
A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC)
2004 · M. Zeuli, A. Gelibter, et al. · Journal of Clinical Oncology · 17
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer
2007 · Alain J. Gelibter, Teresa Gamucci, et al. · Current Medical Research and Opinion · 15
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study
2005 · Alessandra Felici, Paolo Carlini, et al. · Cancer Chemotherapy and Pharmacology · 14
More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine.
1997 · C F Pollera · Journal of Clinical Oncology · 14
Gemcitabine: safety profile unaffected by starting dose.
1996 · C Martin, C F Pollera · PubMed · 12
Changes in serum iron levels following very high-dose cisplatin
1987 · C.F. Pollera, F. Ameglio, et al. · Cancer Chemotherapy and Pharmacology · 11
Improved control of cisplatin-induced emesis with a metoclopramide-dexamethasone combination
1984 · Francesco Cognetti, Paola Pinnaro, et al. · Cancer Chemotherapy and Pharmacology · 11
Impact of gefitinib (‘Iressa’) treatment on the quality of life of patients with advanced non-small-cell lung cancer
2005 · Alain Gelibter, Anna Ceribelli, et al. · Journal of Cancer Research and Clinical Oncology · 10
Works count: 56
Citation count: 1,495
H-index: 17
I10-index: 26
Year
Topic
Type